Literature DB >> 30915770

MiR-155-5p inhibits the proliferation and migration of VSMCs and HUVECs in atherosclerosis by targeting AKT1.

L Chen1, S-Y Zheng, C-Q Yang, B-M Ma, D Jiang.   

Abstract

OBJECTIVE: MiR-155-5p has various biological cellular functions in diverse pathology, including cardiovascular disease. Nevertheless, the role of miR-155-5p in atherosclerosis is still not well known. PATIENTS AND METHODS: The levels of miR-155-5p and AKT Serine/Threonine Kinase 1 (AKT1) in plasma samples from patients with atherosclerotic CAD were detected using quantitative Real-time PCR (qRT-PCR). Cell counting kit-8 (CCK-8) assay was used to analyze the proliferation of vascular smooth muscle cells (VSMCs) and human umbilical vein endothelial cells (HUVECs) in vitro. The migration of VSMCs and HUVECs was detected using wound healing assay. The invasion of VSMCs and HUVECs using was determined using the transwell invasion assay. The expression of AKT1 was measured using immunofluorescence staining analysis.
RESULTS: MiR-155-5p was down-regulated in patients with atherosclerotic CAD. Up-regulation of miR-155-5p inhibited the proliferation, migration and invasion of VSMCs and HUVECs. Bioinformatics analysis and luciferase reporter assay indicated that AKT1 was the direct target of miR-155-5p and miR-155-5p bound to the 3'-untranslated region (3'-UTR) of AKT1. The expression of AKT1 was reduced in cell that was transfected with miR-155-5p. Up-regulation of AKT1 rescued the suppressive effect of miR-155-5p on the growth, migration and invasion of VSMCs and HUVECs. Down-expression of AKT1 partially neutralized the impacts of miR-155-5p on the growth, invasion and migration of VSMCs and HUVECs. Finally, we found that AKT1 was over-regulated in plasma samples of patients with atherosclerotic CAD and its level was negative with the level of miR-155-5p.
CONCLUSIONS: Our study demonstrates that miR-155-5p suppresses the proliferation, migration and invasion of VSMCs and HUVECs through regulating AKT1, which provides the new insights into the precise role of miR-155-5p in atherosclerosis.

Entities:  

Year:  2019        PMID: 30915770     DOI: 10.26355/eurrev_201903_17270

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  13 in total

1.  IL-13 alleviates idiopathic pulmonary hypertension by inhibiting the proliferation of pulmonary artery smooth muscle cells and regulating macrophage infiltration.

Authors:  Ruda Wei; Liting Chen; Pengchuan Li; Chaoyang Lin; Qingshi Zeng
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

2.  Long Noncoding RNA CASC2 Facilitated Wound Healing through miRNA-155/HIF-1α in Diabetic Foot Ulcers.

Authors:  Minjie He; Liang Tu; Ruo Shu; Qi Meng; Sicheng Du; Zhao Xu; Shaoyun Wang
Journal:  Contrast Media Mol Imaging       Date:  2022-06-24       Impact factor: 3.009

3.  Exosomes Derived From CircAkap7-Modified Adipose-Derived Mesenchymal Stem Cells Protect Against Cerebral Ischemic Injury.

Authors:  Limin Xu; Haifeng Ji; Yufeng Jiang; Liying Cai; Xiaoyin Lai; Feifei Wu; Rongguo Hu; Xuelian Yang; Huan Bao; Mei Jiang
Journal:  Front Cell Dev Biol       Date:  2020-10-02

4.  Network Pharmacology-Based Strategy Combined with Molecular Docking and in vitro Validation Study to Explore the Underlying Mechanism of Huo Luo Xiao Ling Dan in Treating Atherosclerosis.

Authors:  Taoli Sun; Wenjuan Quan; Sha Peng; Dongmei Yang; Jiaqin Liu; Chaoping He; Yu Chen; Bo Hu; Qinhui Tuo
Journal:  Drug Des Devel Ther       Date:  2022-05-30       Impact factor: 4.319

5.  Substantially Altered Expression Profile of Diabetes/Cardiovascular/Cerebrovascular Disease Associated microRNAs in Children Descending from Pregnancy Complicated by Gestational Diabetes Mellitus-One of Several Possible Reasons for an Increased Cardiovascular Risk.

Authors:  Ilona Hromadnikova; Katerina Kotlabova; Lenka Dvorakova; Ladislav Krofta; Jan Sirc
Journal:  Cells       Date:  2020-06-26       Impact factor: 6.600

6.  Circulating Exosomal miRNAs as Novel Biomarkers for Stable Coronary Artery Disease.

Authors:  Ping Zhang; Tao Liang; Yao Chen; Xuan Wang; Tianlong Wu; Zhixin Xie; Jianfang Luo; Yanhong Yu; Huimin Yu
Journal:  Biomed Res Int       Date:  2020-12-11       Impact factor: 3.411

7.  Hypermethylation Effects of Yiqihuoxue Decoction in Diabetic Atherosclerosis Using Genome-Wide DNA Methylation Analyses.

Authors:  Qing-Bing Zhou; Yao Chen; Yan Zhang; Dan-Dan Li; Hong-Qin Wang; Zi-Jun Jia; Yu Jin; Feng-Qin Xu; Ying Zhang
Journal:  J Inflamm Res       Date:  2022-01-08

8.  Potential active compounds and molecular mechanism of Xuefu Zhuyu decoction for atherosclerosis, based on network pharmacology and molecular docking.

Authors:  Yingyun Li; Boyu Liu; Lin Liu; Qing Xu; Quan Shen; Weikang Li; Jingshan Zhao
Journal:  Medicine (Baltimore)       Date:  2022-08-12       Impact factor: 1.817

Review 9.  Role of endometrial microRNAs in repeated implantation failure (mini-review).

Authors:  Sepide Goharitaban; Ali Abedelahi; Kobra Hamdi; Mozafar Khazaei; Masoumeh Esmaeilivand; Behrooz Niknafs
Journal:  Front Cell Dev Biol       Date:  2022-08-19

10.  MiR-377-3p inhibits atherosclerosis-associated vascular smooth muscle cell proliferation and migration via targeting neuropilin2.

Authors:  Haijun Wang; Zheng Wei; Hulun Li; Yinghui Guan; Zhiyang Han; Hengzhen Wang; Bing Liu
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.